# Beam Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beam-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.beamtx.com
- Total disclosed funding: $174M
- Latest round: Series B (Mar 6, 2019)
- Investors on record: 9

## About

Beam Therapeutics Inc. is a biotechnology company specializing in precision genetic medicines, utilizing innovative base editing technology to develop therapies for genetic disorders.Founded in 2017 and headquartered in Cambridge, US, Beam Therapeutics Inc. focuses on precision genetic medicine, particularly base editing for genetic disorders. The company has successfully raised a total of USD 180.00 mn, with its most recent funding round being an IPO that took place on February 5, 2020. The company has engaged in a total of four deals since its inception. Keith Joung is the founder of the company, with John Evans currently serving as the CEO.Beam Therapeutics specializes in precision genetic medicines, particularly through an innovative approach known as base editing. Their core product offerings are designed to address the limitations of traditional genetic modification techniques, providing targeted solutions for various genetic disorders. The company's primary focus is on developing and commercializing therapies that can correct genetic mutations at a single base pair level, which could potentially transform the treatment landscape for diseases such as sickle cell disease and beta-thalassemia. Beam Therapeutics employs a suite of delivery technologies, including electroporation and both nonviral and viral delivery methods, to optimize the administration of their therapies. Geographically, their products and services primarily target markets in North America, Europe, and select locations in Asia, catering to healthcare providers, research institutions, and biotechnology firms engaged in genomic medicine.In the most recent fiscal year of 2024, Beam Therapeutics reported a revenue of USD 63.52 mn. The company generated this revenue through collaborations and partnerships with pharmaceutical companies and research institutions, focusing on the development and commercialization of its base editing technology. The agreements typically involve licensing arrangements that include fees or royalties based on the commercialization of therapies developed using Beam's technology, as well as milestone payments tied to development progress.Beam Therapeutics plans to utilize the funds raised from its IPO in February 2020 to further expand its base editing technology offerings and explore new therapeutic areas. The company is actively designing new products aimed at addressing additional genetic disorders, with plans to launch these therapies in the next few years. Furthermore, Beam has identified international markets for expansion, specifically targeting Europe and Asia, by the end of 2025. The recent funding will support these initiatives, including research and development efforts to expedite the product pipeline and enhance their market presence.

## Funding rounds

- Series B, Mar 6, 2019, $135M — ARCH Venture Partners, Eight Roads Ventures, F-Prime Capital, Altitude Life Science Ventures, GV, Omega Funds, Redmile Group, Cormorant Asset Management
- Series A, May 11, 2018, $39M — ARCH Venture Partners, OUP (Osage University Partners), F-Prime Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A, Series B
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series B
- Altitude Life Science Ventures (https://capitalatlas.ai/funds/altitude-life-science-ventures) — Series B
- GV (https://capitalatlas.ai/funds/gv) — Series B
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series B
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B